TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06827236: A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That

Sponsor: BioNTech SE · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 380 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT06827236 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06827236 Rescue Dossier →